Top

Diabetologia

Published in:

01-01-2008 | Consensus statement update

Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy

Update regarding the thiazolidinediones

Authors: D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin, B. Zinman

Published in: Diabetologia | Issue 1/2008

Excerpt

The consensus algorithm for the management of type 2 diabetes mellitus was developed on behalf of the American Diabetes Association and the European Association for the Study of Diabetes approximately 1 year ago [1, 2]. This evidence-based algorithm was developed to help guide healthcare providers to choose the most appropriate treatment regimens from an ever-expanding list of approved medications. The authors continue to endorse the major features of the algorithm, including the need to achieve and maintain glycaemia within or as close to the non-diabetic range as is safely possible; the initiation of lifestyle interventions and treatment with metformin at the time of diagnosis; the rapid addition of medications and transition to new regimens when target glycaemia is not achieved; and the early addition of insulin therapy in patients who do not meet target HbA_1c levels. …

Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 29:1963–1972PubMedCrossRef

Nathan DM, Buse JB, Davidson MB et al (2006) Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 49:1711–1721PubMedCrossRef

Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMedCrossRef

Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195PubMedCrossRef

GalaxoSmithKline (2007) Advisory committee briefing document: cardiovascular safety of rosiglitazone. GalaxoSmithKline, Philadelphia, pp 40–45. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-01-sponsor-backgrounder.pdf, accessed 25 October 2007

US Food and Drug Administration (2007) FDA briefing document. FDA, Rockville, pp 13–105. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4308b1-02-fda-backgrounder.pdf, accessed 25 October 2007

Psaty BM, Furberg CD (2007) Rosiglitazone and cardiovascular risk. N Engl J Med 356:2522–2524PubMedCrossRef

Drazen JM, Morrissey S, Curfman GD (2007) Rosiglitazone—continued uncertainty about safety. N Engl J Med 357:63–64PubMedCrossRef

Nathan DM (2007) Rosiglitazone and cardiotoxicity—weighing the evidence. N Engl J Med 357:64–66PubMedCrossRef

10.

Psaty BM, Furberg CD (2007) The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med 357:67–69PubMedCrossRef

11.

Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomized clinical trials. Lancet 370:1129–1136PubMedCrossRef

12.

Home PD, Pocock SJ, Beck-Nielsen H, for the RECORD Study Group et al (2007) Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 357:28–38PubMedCrossRef

13.

Lincoff AM, Wolski K, Nicholls SJ, Nissen SE (2007) Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298:1180–1188PubMedCrossRef

14.

Singh S, Loke YK, Furberg CD (2007) Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30:2248–2253CrossRef

15.

US Food and Drug Administration: Center for Drug Evaluation and Research (2007) Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) information. Available from: http://fda.gov/cder/drug/infopage/rosiglitazone/default.htm, accessed 25 October 2007

16.

Schwartz AV, Sellmeyer DE, Vittinghoff E et al (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349–3354PubMedCrossRef

17.

Kahn SE, Haffner SM, Heise MA et al (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355:2427–2442PubMedCrossRef

Title: Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Update regarding the thiazolidinediones
Authors: D. M. Nathan
J. B. Buse
M. B. Davidson
E. Ferrannini
R. R. Holman
R. Sherwin
B. Zinman
Publication date: 01-01-2008
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 1/2008
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-007-0873-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2008

TUB is a candidate gene for late-onset obesity in women

Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells

Effect of α-tocopherol and β-carotene supplementation on the incidence of type 2 diabetes

Evaluating the association of common LMNA variants with type 2 diabetes and quantitative metabolic phenotypes in French Europids

R-α-Lipoic acid and acetyl-l-carnitine complementarily promote mitochondrial biogenesis in murine 3T3-L1 adipocytes

No evidence that established type 2 diabetes susceptibility variants in the PPARG and KCNJ11 genes have pleiotropic effects on early growth

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials